Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Up 68.6% in July

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 87,153 shares, an increase of 68.6% from the July 15th total of 51,687 shares. Based on an average trading volume of 119,074 shares, the short-interest ratio is currently 0.7 days. Currently, 14.5% of the company’s shares are sold short.

Analysts Set New Price Targets

JAGX has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. Wall Street Zen upgraded shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Jaguar Animal Health Stock Performance

Shares of Jaguar Animal Health stock opened at $0.98 on Wednesday. The business’s 50 day simple moving average is $1.83 and its 200 day simple moving average is $9.51. Jaguar Animal Health has a 52-week low of $0.72 and a 52-week high of $85.40. The firm has a market cap of $585,900.00, a PE ratio of -0.00 and a beta of -0.06.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($149.10) by $135.50. The firm had revenue of $20.27 million for the quarter, compared to analyst estimates of $4.21 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.